TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21492 DO - 10.3322/caac.21492 ID - Bray2018 ER - TY - JOUR AU - Daly, M. B. AU - Ozols, R. F. PY - 2004 DA - 2004// TI - Symptoms of ovarian cancer--where to set the bar? JO - JAMA VL - 291 UR - https://doi.org/10.1001/jama.291.22.2755 DO - 10.1001/jama.291.22.2755 ID - Daly2004 ER - TY - JOUR AU - Bast, R. C. AU - Brewer, M. AU - Zou, C. PY - 2007 DA - 2007// TI - Prevention and early detection of ovarian cancer: mission impossible? JO - Recent Results Cancer Res VL - 174 UR - https://doi.org/10.1007/978-3-540-37696-5_9 DO - 10.1007/978-3-540-37696-5_9 ID - Bast2007 ER - TY - JOUR AU - Lorusso, D. AU - Tripodi, E. AU - Maltese, G. PY - 2018 DA - 2018// TI - Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy JO - Drug Des Devel Ther VL - 12 UR - https://doi.org/10.2147/DDDT.S124447 DO - 10.2147/DDDT.S124447 ID - Lorusso2018 ER - TY - JOUR AU - Ozols, R. F. PY - 1999 DA - 1999// TI - Chemotherapy for ovarian cancer JO - Semin Oncol VL - 26 ID - Ozols1999 ER - TY - JOUR AU - Bois, A. AU - Lück, H. -. J. AU - Meier, W. PY - 2003 DA - 2003// TI - A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer JO - J Natl Cancer Inst VL - 95 UR - https://doi.org/10.1093/jnci/djg036 DO - 10.1093/jnci/djg036 ID - Bois2003 ER - TY - JOUR AU - Aabo, K. AU - Adams, M. AU - Adnitt, P. PY - 1998 DA - 1998// TI - Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced ovarian Cancer Trialists’ Group JO - Br J Cancer VL - 78 UR - https://doi.org/10.1038/bjc.1998.710 DO - 10.1038/bjc.1998.710 ID - Aabo1998 ER - TY - JOUR AU - Bois, A. AU - Neijt, J. P. AU - Thigpen, J. T. PY - 1999 DA - 1999// TI - First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care? JO - Ann Oncol VL - 10 UR - https://doi.org/10.1023/A:1008355317514 DO - 10.1023/A:1008355317514 ID - Bois1999 ER - TY - JOUR AU - Ozols, R. F. AU - Bundy, B. N. AU - Greer, B. E. PY - 2003 DA - 2003// TI - Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.02.153 DO - 10.1200/JCO.2003.02.153 ID - Ozols2003 ER - TY - JOUR AU - West, R. J. AU - Zweig, S. F. PY - 1997 DA - 1997// TI - Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide JO - Eur J Gynaecol Oncol VL - 18 ID - West1997 ER - TY - JOUR AU - Piccart, M. J. AU - Bertelsen, K. AU - James, K. PY - 2000 DA - 2000// TI - Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.9.699 DO - 10.1093/jnci/92.9.699 ID - Piccart2000 ER - TY - JOUR AU - Neijt, J. P. AU - Engelholm, S. A. AU - Tuxen, M. K. PY - 2000 DA - 2000// TI - Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer JO - J Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.17.3084 DO - 10.1200/JCO.2000.18.17.3084 ID - Neijt2000 ER - TY - JOUR AU - Muggia, F. M. AU - Braly, P. S. AU - Brady, M. F. PY - 2000 DA - 2000// TI - Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian Cancer: a gynecologic oncology group study JO - J Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.1.106 DO - 10.1200/JCO.2000.18.1.106 ID - Muggia2000 ER - TY - JOUR AU - McGuire, W. P. AU - Hoskins, W. J. AU - Brady, M. F. PY - 1996 DA - 1996// TI - Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian Cancer JO - N Engl J Med VL - 334 UR - https://doi.org/10.1056/NEJM199601043340101 DO - 10.1056/NEJM199601043340101 ID - McGuire1996 ER - TY - JOUR PY - 2002 DA - 2002// TI - Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial JO - Lancet VL - 360 UR - https://doi.org/10.1016/S0140-6736(02)09738-6 DO - 10.1016/S0140-6736(02)09738-6 ID - ref15 ER - TY - JOUR AU - Kehoe, S. AU - Hook, J. AU - Nankivell, M. PY - 2015 DA - 2015// TI - Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial JO - Lancet VL - 386 UR - https://doi.org/10.1016/S0140-6736(14)62223-6 DO - 10.1016/S0140-6736(14)62223-6 ID - Kehoe2015 ER - TY - JOUR AU - Vergote, I. AU - Tropé, C. G. AU - Amant, F. PY - 2010 DA - 2010// TI - Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian Cancer JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa0908806 DO - 10.1056/NEJMoa0908806 ID - Vergote2010 ER - TY - JOUR AU - Pölcher, M. AU - Mahner, S. AU - Ortmann, O. PY - 2009 DA - 2009// TI - Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR) JO - Oncol Rep VL - 22 UR - https://doi.org/10.3892/or_00000479 DO - 10.3892/or_00000479 ID - Pölcher2009 ER - TY - JOUR AU - Perren, T. J. AU - Swart, A. M. AU - Pfisterer, J. PY - 2011 DA - 2011// TI - A phase 3 trial of bevacizumab in ovarian cancer JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103799 DO - 10.1056/NEJMoa1103799 ID - Perren2011 ER - TY - JOUR AU - Burger, R. A. AU - Brady, M. F. AU - Bookman, M. A. PY - 2011 DA - 2011// TI - Incorporation of bevacizumab in the primary treatment of ovarian cancer JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1104390 DO - 10.1056/NEJMoa1104390 ID - Burger2011 ER - TY - JOUR AU - Oza, A. M. AU - Cook, A. D. AU - Pfisterer, J. PY - 2015 DA - 2015// TI - Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00086-8 DO - 10.1016/S1470-2045(15)00086-8 ID - Oza2015 ER - TY - JOUR AU - Ledermann, J. A. PY - 2016 DA - 2016// TI - PARP inhibitors in ovarian cancer JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw094 DO - 10.1093/annonc/mdw094 ID - Ledermann2016 ER - TY - JOUR AU - Mirza, M. R. AU - Pignata, S. AU - Ledermann, J. A. PY - 2018 DA - 2018// TI - Latest clinical evidence and further development of PARP inhibitors in ovarian cancer JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy174 DO - 10.1093/annonc/mdy174 ID - Mirza2018 ER - TY - JOUR AU - Moore, K. AU - Colombo, N. AU - Scambia, G. PY - 2018 DA - 2018// TI - Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1810858 DO - 10.1056/NEJMoa1810858 ID - Moore2018 ER - TY - JOUR AU - Pujade-Lauraine, E. AU - Ledermann, J. A. AU - Selle, F. PY - 2017 DA - 2017// TI - Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30469-2 DO - 10.1016/S1470-2045(17)30469-2 ID - Pujade-Lauraine2017 ER - TY - JOUR AU - Petit, T. AU - Velten, M. AU - d’Hombres, A. PY - 2007 DA - 2007// TI - Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy JO - Gynecol Oncol VL - 104 UR - https://doi.org/10.1016/j.ygyno.2006.07.034 DO - 10.1016/j.ygyno.2006.07.034 ID - Petit2007 ER - TY - JOUR AU - Wong, R. AU - Milosevic, M. AU - Sturgeon, J. PY - 1999 DA - 1999// TI - Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: results of a prospective treatment protocol JO - Int J Radiat Oncol Biol Phys VL - 45 UR - https://doi.org/10.1016/S0360-3016(99)00227-8 DO - 10.1016/S0360-3016(99)00227-8 ID - Wong1999 ER - TY - JOUR AU - Whelan, T. J. AU - Dembo, A. J. AU - Bush, R. S. PY - 1992 DA - 1992// TI - Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer JO - Int J Radiat Oncol Biol Phys VL - 22 UR - https://doi.org/10.1016/0360-3016(92)90779-H DO - 10.1016/0360-3016(92)90779-H ID - Whelan1992 ER - TY - JOUR AU - Ledermann, J. A. AU - Dembo, A. J. AU - Sturgeon, J. F. PY - 1991 DA - 1991// TI - Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation JO - Gynecol Oncol VL - 41 UR - https://doi.org/10.1016/0090-8258(91)90250-9 DO - 10.1016/0090-8258(91)90250-9 ID - Ledermann1991 ER - TY - JOUR PY - 2003 DA - 2003// TI - Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment JO - Int J Gynecol Cancer VL - 13 UR - https://doi.org/10.1046/j.1525-1438.2003.13193.x DO - 10.1046/j.1525-1438.2003.13193.x ID - ref30 ER - TY - JOUR AU - Einhorn, N. AU - Lundell, M. AU - Nilsson, B. PY - 1999 DA - 1999// TI - Is there place for radiotherapy in the treatment of advanced ovarian cancer? JO - Radiother Oncol VL - 53 UR - https://doi.org/10.1016/S0167-8140(99)00144-9 DO - 10.1016/S0167-8140(99)00144-9 ID - Einhorn1999 ER - TY - JOUR AU - Fyles, A. W. AU - Dembo, A. J. AU - Bush, R. S. PY - 1992 DA - 1992// TI - Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma JO - Int J Radiat Oncol Biol Phys VL - 22 UR - https://doi.org/10.1016/0360-3016(92)90778-G DO - 10.1016/0360-3016(92)90778-G ID - Fyles1992 ER - TY - JOUR AU - Dinniwell, R. AU - Lock, M. AU - Pintilie, M. PY - 2005 DA - 2005// TI - Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer JO - Int J Radiat Oncol Biol Phys VL - 62 UR - https://doi.org/10.1016/j.ijrobp.2004.09.010 DO - 10.1016/j.ijrobp.2004.09.010 ID - Dinniwell2005 ER - TY - JOUR AU - Pickel, H. AU - Lahousen, M. AU - Petru, E. PY - 1999 DA - 1999// TI - Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian Cancer JO - Gynecol Oncol VL - 72 UR - https://doi.org/10.1006/gyno.1998.5184 DO - 10.1006/gyno.1998.5184 ID - Pickel1999 ER - TY - JOUR AU - Mundt, A. J. AU - Lujan, A. E. AU - Rotmensch, J. PY - 2002 DA - 2002// TI - Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies JO - Int J Radiat Oncol Biol Phys VL - 52 UR - https://doi.org/10.1016/S0360-3016(01)02785-7 DO - 10.1016/S0360-3016(01)02785-7 ID - Mundt2002 ER - TY - JOUR AU - Hurkmans, C. W. AU - Cho, B. C. J. AU - Damen, E. PY - 2002 DA - 2002// TI - Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation JO - Radiother Oncol VL - 62 UR - https://doi.org/10.1016/S0167-8140(01)00473-X DO - 10.1016/S0167-8140(01)00473-X ID - Hurkmans2002 ER - TY - JOUR AU - Rochet, N. AU - Sterzing, F. AU - Jensen, A. D. PY - 2010 DA - 2010// TI - Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/Taxane chemotherapy for advanced ovarian Cancer: phase I study JO - Int J Radiat Oncol Biol Phys VL - 76 UR - https://doi.org/10.1016/j.ijrobp.2009.03.061 DO - 10.1016/j.ijrobp.2009.03.061 ID - Rochet2010 ER - TY - JOUR AU - Rochet, N. AU - Kieser, M. AU - Sterzing, F. PY - 2011 DA - 2011// TI - Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - the OVAR-IMRT-02 study JO - BMC Cancer VL - 11 UR - https://doi.org/10.1186/1471-2407-11-41 DO - 10.1186/1471-2407-11-41 ID - Rochet2011 ER - TY - JOUR AU - Arians, N. AU - Kieser, M. AU - Benner, L. PY - 2017 DA - 2017// TI - Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): first results of a prospective phase 2 study JO - Int J Radiat Oncol Biol Phys VL - 99 UR - https://doi.org/10.1016/j.ijrobp.2017.06.2465 DO - 10.1016/j.ijrobp.2017.06.2465 ID - Arians2017 ER - TY - BOOK PY - 2018 DA - 2018// TI - A language and environment for statistical computing PB - R Foundation for Statistical Computing CY - Vienna ID - ref40 ER - TY - JOUR AU - Cannistra, S. A. AU - Bast, R. C. AU - Berek, J. S. PY - 2003 DA - 2003// TI - Progress in the management of gynecologic cancer: consensus summary statement JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.04.003 DO - 10.1200/JCO.2003.04.003 ID - Cannistra2003 ER - TY - JOUR AU - Lambert, H. E. AU - Gregory, W. M. AU - Nelstrop, A. E. PY - 2004 DA - 2004// TI - Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population JO - Int J Gynecol Cancer VL - 14 UR - https://doi.org/10.1136/ijgc-00009577-200409000-00006 DO - 10.1136/ijgc-00009577-200409000-00006 ID - Lambert2004 ER -